Hjem › Overvægt › North Carolina
Overvægt kliniske forsøg i North Carolina
40 studier for Overvægt søger deltagere på steder i North Carolina.
Byer i North Carolina
- Havelock17 studier
- Charlotte15 studier
- Greensboro12 studier
- Wilmington11 studier
- Durham7 studier
- Winston-Salem6 studier
- Statesville5 studier
- Raleigh5 studier
- Cary4 studier
- Fayetteville4 studier
- New Bern4 studier
- Greenville3 studier
Officiel studietekst (engelsk)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Medication Management /ID# 281965, Greensboro
- Monroe Biomedical Research /ID# 282009, Monroe
- Centricity Research - Morehead city /ID# 283264, Morehead City
- og 2 flere
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07752979FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
- University of North Carolina at Chapel Hill, Chapel Hill
Rekrutterer
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT06724406Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- TMA Headlands, Wilmington
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 28. sep. 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Medication Mgmnt, LLC_Grnsboro, Greensboro
- Accellacare of Raleigh, Raleigh
- Accellacare-Salisbury PMG Res, Salisbury
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- PharmQuest Life Sciences LLC, Greensboro
- Piedmont Healthcare/Research, Statesville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- West Clinical Research, Morehead City
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Medication Management, LLC, Greensboro
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Statesville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07776509Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UNC Children's Hospital, Chapel Hill
- Duke Children's Primary Care, Durham
- Lucas Research, Inc, Morehead City
RekruttererFase 3
Alder 6 til 17 · Alle køn · Opdateret 24. sep. 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Coastal Research Institute - Fayetteville, Fayetteville
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- PharmQuest Life Sciences, LLC, Greensboro
- West Clinical Research, Morehead City
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- University of North Carolina Medical Center, Chapel Hill
- Medication Management, Greensboro
- Carteret Medical Group, Morehead City
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Monroe
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Novant Health Heart and Vascular Institute, Charlotte
- Velocity Clinical Research - Durham, Durham
- Moses H Cone Memorial Hospital, Greensboro
- og 7 flere
RekruttererFase 3
Alder 45 til 99 · Alle køn · Opdateret 22. sep. 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Monroe
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- og 1 flere
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 22. sep. 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Charlotte
- AURORA-1 Clinical Site, Greenville
- AURORA-1 Clinical Site, Morehead City
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Charlotte
- AURORA-2 Clinical Site, Durham
- AURORA-2 Clinical Site, Greenville
- og 2 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Centricity Research Morehead City Multispeciality, Morehead City
- Wake Forest University Health Sciences, Winston-Salem
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Lucas Research, Inc., Morehead City
- Shelby Clinical Research, Shelby
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Charlotte
- ACCOMPLISH-2 Research Site, Durham
- ACCOMPLISH-2 Research Site, Fayetteville
- og 2 flere
RekruttererFase 3Frivillige med god helbredstilstand velkomne
Alder 18 til 79 · Alle køn · Opdateret 11. sep. 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- og 1 flere
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 8. sep. 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Revival Research Institute, LLC, Cary
- Onsite Clinical Solutions - Huntersville, Huntersville
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- PharmQuest, Greensboro
- KDCILM, LLC & Accellacare US, Inc., Wilmington
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07745504Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Greensboro
- Kailera Clinical Site, Monroe
- Kailera Clinical Site, Morehead City
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Accellacare of Hickory, Hickory
- Carolina Research Center Inc, Shelby
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- West Clinical Research, Morehead City
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07684144Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Centricity Research Morehead City Specialty, Morehead City
- Accellacare of Raleigh, Raleigh
- Accellacare Research of Wilmington, Wilmington
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 27. aug. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Statesville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Piedmont Healthcare/Research, Statesville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Charlotte
- ACCOMPLISH-1 Research Site, Durham
- ACCOMPLISH-1 Research Site, Fayetteville
- og 3 flere
RekruttererFase 3
Alder 18 til 79 · Alle køn · Opdateret 10. aug. 2026 · NCT07654361Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Monroe Biomedical Research, LLC, Monroe
- Accellacare, Wilmington
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. jun. 2026 · NCT07607587A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
- Monroe Biomedical Research, Monroe
RekruttererFase 2
Alder 18 til 60 · Alle køn · Opdateret 22. jun. 2026 · NCT07570758Pregnancy Exercise Mode Effect on Childhood Obesity
- East Carolina University, Greenville
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 til 45 · Kvinder · Opdateret 4. jun. 2026 · NCT04805502NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- Wake Forest University Health Sciences, Winston-Salem
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 til 39 · Kvinder · Opdateret 27. feb. 2026 · NCT05674799A Mobile Intervention to Reduce Pain and Improve Health-III
- Wake Forest University, Winston-Salem
RekruttererFase 2
Alder 65 og opefter · Alle køn · Opdateret 20. feb. 2026 · NCT06623669MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
- True You Weight Loss, Cary
- True You Weight Loss, Cary
Rekrutterer
Alder 21 til 65 · Alle køn · Opdateret 21. mar. 2025 · NCT06734312REvision of VSG with Ablation of the Mucosa Procedure
- True You Weight Loss, Cary
Rekrutterer
Alder 22 til 60 · Alle køn · Opdateret 5. nov. 2024 · NCT06671119Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.